This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

GR-MD-02 Plus Pembrolizumab in Melanoma Patients

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2016 by Providence Health & Services
Sponsor:
Collaborator:
Galectin Therapeutics Inc.
Information provided by (Responsible Party):
Providence Health & Services
ClinicalTrials.gov Identifier:
NCT02575404
First received: October 9, 2015
Last updated: June 23, 2016
Last verified: June 2016
  Purpose
This study is a dose escalation of GR-MD-02 with the standard therapeutic dose of pembrolizumab in patients with advanced melanoma.

Condition Intervention Phase
Melanoma Drug: GR-MD-02 Drug: Pembrolizumab Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma

Resource links provided by NLM:


Further study details as provided by Providence Health & Services:

Primary Outcome Measures:
  • Frequency and Severity of Treatment-Related Adverse Events Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [ Time Frame: 85 Days ]
    Patients are seen in clinic 7 times over 85 days. At each visit, a research nurse performs a toxicity check. Patients have 5 physical exams during the 85-day period.


Secondary Outcome Measures:
  • Measure the response rate to combined therapy with GR-MD-02 and pembrolizumab in patients with metastatic melanoma. [ Time Frame: Baseline and at Day 85 ]
    Patients will have PET and CT scans at baseline and after 85 days to assess response to treatment.

  • Assess the biological activity of GR-MD-02 in combination with pembrolizumab. [ Time Frame: 85 Days ]
    Patients will provide 5 blood samples over 85 days to measure the absolute number of CD4+T Cells, CD8+ T cells and melanoma-specific T cells


Estimated Enrollment: 22
Study Start Date: October 2015
Estimated Study Completion Date: October 2021
Estimated Primary Completion Date: October 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 2 mg/kg GR-MD-02
2 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
Drug: GR-MD-02
Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
Other Name: Galactoarabino-rhamnogalactouronate
Drug: Pembrolizumab
Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
Other Name: Keytruda
Experimental: 4 mg/kg GR-MD-02
4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
Drug: GR-MD-02
Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
Other Name: Galactoarabino-rhamnogalactouronate
Drug: Pembrolizumab
Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
Other Name: Keytruda
Experimental: 8 mg/kg GR-MD-02
8 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
Drug: GR-MD-02
Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
Other Name: Galactoarabino-rhamnogalactouronate
Drug: Pembrolizumab
Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
Other Name: Keytruda

Detailed Description:
This study will employ a 3+3 phase I design with dose escalation of GR-MD-02 in conjunction with the standard therapeutic dose of pembrolizumab in patients with advanced melanoma who have had progression after ipilimumab and/or BRAF targeted therapy when a BRAF mutation is present. In addition to monitoring for toxicity and clinical response, blood and tumor samples will be obtained to assess immunologic measures relevant to galectin biology and pembrolizumab T-cell checkpoint inhibition.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with metastatic or unresectable melanoma for whom treatment with pembrolizumab is indicated. Histological confirmation of melanoma will be required by previous biopsy or cytology.
  • Patients who have radiographic progression using Response Evaluation Criteria In Solid Tumors (RECIST) currently on pembrolizumab are also eligible.
  • Patients must be ≥ 18 years of age.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • Women of childbearing potential must have a serum or urine pregnancy test performed within 72 hours prior to the start of protocol treatment. The results of this test must be negative in order for the patient to be eligible. In addition, women of childbearing potential as well as male patients must agree to take appropriate precautions to avoid pregnancy.
  • No active bleeding.
  • Anticipated lifespan greater than 12 weeks.
  • Patients must sign a study-specific consent document.

Exclusion Criteria:

  • Patients who have previously received a galectin antagonist
  • Patients with active autoimmune disease except for autoimmune thyroiditis or vitiligo
  • Patients with history of colitis
  • Patients with untreated brain metastases. Patients with treated brain metastases who demonstrate control of brain metastases with follow-up imaging 4 or more weeks after initial therapy are eligible.
  • Other active metastatic cancer requiring treatment.
  • Patients with active infection requiring antibiotics.
  • Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.
  • Need for chronic steroids. Inhaled corticosteroids are acceptable.
  • Laboratory values (to be performed within 28 days of enrollment) outside of protocol-specified ranges.
  • Inability to give informed consent and comply with the protocol. Patients with a history of psychiatric illness must be judged able to understand fully the investigational nature of the study and the risks associated with the therapy.
  • Any medical condition that in the opinion of the Principal Investigator would compromise the safety or conduct of the study procedures.
  • Unresolved immune-mediated pneumonitis, diarrhea, elevation of hepatocellular enzymes or other toxicities requiring greater than physiological replacement doses of steroids.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02575404

Contacts
Contact: Chris Fountain, RN 503-215-2691 christopher.fountain@providence.org
Contact: Brenda Fisher, RN 503-215-2613 brenda.fisher@providence.org

Locations
United States, Oregon
Providence Cancer Center Recruiting
Portland, Oregon, United States, 97213
Contact: Chris Fountain, RN    503-215-2691    christopher.fountain@providence.org   
Contact: Brenda Fisher, RN    503-215-2613    brenda.fisher@providence.org   
Sub-Investigator: Walter J. Urba, M.D., Ph.D         
Sub-Investigator: Rachel Sanborn, MD         
Sub-Investigator: Todd Crocenzi, MD         
Sub-Investigator: Rui Li, MD, PhD         
Sub-Investigator: Rom Leidner, MD         
Principal Investigator: Brendan Curti, MD         
Sub-Investigator: Alison Conlin, MD         
Sub-Investigator: John Godwin, MD         
Sub-Investigator: David Page, MD         
Sponsors and Collaborators
Providence Health & Services
Galectin Therapeutics Inc.
Investigators
Principal Investigator: Brendan Curti, MD Providence Health & Services
  More Information

Additional Information:
Responsible Party: Providence Health & Services
ClinicalTrials.gov Identifier: NCT02575404     History of Changes
Other Study ID Numbers: 15-166
Study First Received: October 9, 2015
Last Updated: June 23, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Providence Health & Services:
Metastatic
Keytruda
pembrolizumab
GR-MD-02
Galactoarabino-rhamnogalacturonate
Immunotherapy

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Pembrolizumab
Antineoplastic Agents

ClinicalTrials.gov processed this record on August 23, 2017